Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia
Latest Information Update: 26 Dec 2023
At a glance
- Drugs Copanlisib (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 18 Dec 2023 According to Clinicaltrials.gov, the study is Terminated as the Sponsor halted clinical development of study drug.
- 18 Dec 2023 Status changed from recruiting to discontinued.
- 28 Jun 2022 Planned End Date changed from 1 Mar 2022 to 1 May 2024.